Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. NKTR-118, an oral peripherally-acting opioid antagonist, is a late stage investigational product candidate in clinical development for the treatment of opioid-induced constipation. NKTR-118 was developed by Nektar, utilizing its proprietary small molecule advanced polymer conjugate technology platform.

Today's presentation at AAPM includes topline data previously announced by the company in March 2009. In a Phase 2 double-blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 met the primary endpoint of increase in spontaneous bowel movements over the baseline period. There was no reversal or reduction of opioid-mediated analgesia in any dose groups. NKTR-118 was also well tolerated with the most commonly reported side effects being dose-dependent gastrointestinal-related effects.

Download Today's Poster Presentation for NKTR-118

The poster presentation from today's AAPM 20th Annual Clinical Meeting can be found on Nektar's website at http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html

AAPM Poster #39: "NKTR-118 Significantly Reverses Opioid-Induced Constipation"

Complete Data from NKTR-118 Phase 2 Clinical Trial to be presented in Oral Plenary Session at ACG 2009

Data from the Phase 2 clinical trial of NKTR-118 have been accepted for presentation in an oral plenary session of the American College of Gastroenterology (ACG
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... PHILADELPHIA, Dec. 15 The Center ... Advanstar Communications, is pleased to announce the ... Pharmaceutical/Biotech Accounting and Reporting Congress . The ... Philadelphia, on March 16-17, 2010. ,, Over ... professionals have attended this premier event since ...
(Date:12/15/2009)... December 15 , ... to Evaluate the Ability of,Cardiopoietic Cells to Restore ... BioSciences, a leading Belgian biotechnology company specialising,in cell-based ... that it has completed, two months ahead of ... Phase II/III trial of C-Cure, a,unique stem cell ...
(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...
(Date:12/14/2009)... -- The third edition of Infusion ... published by the Infusion Nurses Society (INS), includes ... Anthracyclines are a group of chemotherapy medications ... been used in the treatment of various types ... ,, According to the INS publication: "In September ...
Breaking Biology Technology:CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
... BOSTON, July 16 PAREXEL International,Corporation (Nasdaq: ... today that it has promoted Mark A. Goldberg, ... served as,President of Clinical Research Services and Perceptive ... areas of the Company and report,to Josef von ...
... 16 The Repair Stem Cell Institute LLC,(RSCI; ... global,public affairs organization, today announced the formation of ... of the world,s leading stem cell,medical, science and ... has offices located in Washington, D.C. and Bangkok., ...
... Bio-,pharmaceutical Technology Inc. (OTC Bulletin Board: HFGB) a ... raw materials,for use in pharmaceutical, nutraceutical and food ... has established a strategic alliance with,Premier Media Service ... imaging and creating retail market awareness for the ...
Other Biology Technology:PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 3PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 4Repair Stem Cell Institute Announces Science Advisory Board 2Repair Stem Cell Institute Announces Science Advisory Board 3Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc. 2Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc. 3
(Date:12/15/2009)... woolly mammoths and ancient American horses may have ... thousand years longer than previously thought. After plucking ... a team of researchers used cutting-edge techniques to ... permafrost samples dated to between 7,600 and 10,500 ... least one population of these now-extinct mammals endured ...
(Date:12/15/2009)... can look forward to ultra-low powered or self ... mobile phones. This is made possible with power ... critical elements for power optimisation and higher energy ... IC design is the key enabling capability for ... nation in advanced analog and mixed signal design ...
(Date:12/14/2009)... an international team that has used DNA samples from ... of North America,s woolly mammoths and ancient horses. , ... Sciences professor Duane Froese and his colleagues counters an ... and teeth. That analysis concluded that more than half ... disappeared about 13,000 years ago. , In the ...
Breaking Biology News(10 mins):Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Aprima Improves Medical Practices 26apos 3B Coding and Billing Accuracy with Intelligent Medical Objects 26apos 3B Tools 59036 1Aprima Improves Medical Practices 26apos 3B Coding and Billing Accuracy with Intelligent Medical Objects 26apos 3B Tools 59036 2Aprima Improves Medical Practices 26apos 3B Coding and Billing Accuracy with Intelligent Medical Objects 26apos 3B Tools 59036 3Aprima Improves Medical Practices 26apos 3B Coding and Billing Accuracy with Intelligent Medical Objects 26apos 3B Tools 59036 4Cardiovascular Systems Announces Plans for Second Manufacturing Facility New Facility Expands CSI 26apos 3Bs Capacity to Produce Peripheral Arterial 59031 1Cardiovascular Systems Announces Plans for Second Manufacturing Facility New Facility Expands CSI 26apos 3Bs Capacity to Produce Peripheral Arterial 59031 2Cardiovascular Systems Announces Plans for Second Manufacturing Facility New Facility Expands CSI 26apos 3Bs Capacity to Produce Peripheral Arterial 59031 3Cardiovascular Systems Announces Plans for Second Manufacturing Facility New Facility Expands CSI 26apos 3Bs Capacity to Produce Peripheral Arterial 59031 4Clinical Genomics Continues Collaborative Research With CSIRO 14380 1Clinical Genomics Continues Collaborative Research With CSIRO 14380 2
... the first time that a new type of gene ... in a live animal., The study, which was published ... RNA interference can rescue a strain of mouse that ... hormone that interferes with normal growth. When the gene ...
... structures with pores at both the nanometer and micron ... next generation of detonators used to improve the reliability, ... military munitions. , Developed by a team ... and the Indian Head Division of the Naval Surface ...
... to getting fit, according to researchers from the University of ... a built-in ability to judge how hard our bodies are ... studies over the last two years, culminating in three academic ... close correlation between actual and perceived exertion in people of ...
Other Biology News:RNA interference therapy heals growth deficiency disorder in a live animal 2RNA interference therapy heals growth deficiency disorder in a live animal 3RNA interference therapy heals growth deficiency disorder in a live animal 4Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3Built-in exercise monitor predicts fitness 2